The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

Imidaprilat     (4S)-3-[(2S)-2-[[(1S)-1- carboxy-3-phenyl...

Synonyms: CHEMBL99701, SureCN677222, AG-H-61749, CHEBI:264806, AC1NUZ5P, ...
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Imidaprilat


High impact information on Imidaprilat


Chemical compound and disease context of Imidaprilat


Biological context of Imidaprilat


Anatomical context of Imidaprilat


Associations of Imidaprilat with other chemical compounds


Gene context of Imidaprilat

  • Consistently, sympatho-facilitation by Ang I, which could be abolished by the angiotensin converting enzyme (ACE) inhibitor imidaprilat, was apparently greater than that of Ang II in SHR, despite no difference in WKY [13].
  • Either imidaprilat or cilazaprilat increased CBF, FS, and LER with increases in cardiac bradykinin and NO levels [14].
  • After incubating with the various plasma samples, imidapril was mainly metabolized to the pharmacologically active metabolite, 6366 A (M1, CAS 89371-44-8), in rat plasma; on the other hand, the ester bond of imidapril was not hydrolyzed in dog, monkey, and human plasma [15].

Analytical, diagnostic and therapeutic context of Imidaprilat


  1. Comparison of the effect of imidaprilat and ramiprilat on broncho-constriction and hypotension induced by bradykinin in guinea pigs. Doi, H., Narita, H. Inflamm. Res. (2000) [Pubmed]
  2. Pharmacokinetics of imidapril and its active metabolite imidaprilat following single dose and during steady state in patients with impaired liver function. Hoogkamer, J.F., Kleinbloesem, C.H., Nokhodian, A., Ouwerkerk, M.J., Lankhaar, G., Ungethüm, W., Kirch, W. Eur. J. Clin. Pharmacol. (1997) [Pubmed]
  3. Protective effect of imidaprilat, an angiotensin-converting enzyme inhibitor on *OH generation in rat myocardium. Obata, T., Yamanaka, Y. Biochim. Biophys. Acta (1999) [Pubmed]
  4. Clinical pharmacokinetics and selective pharmacodynamics of new angiotensin converting enzyme inhibitors: an update. Song, J.C., White, C.M. Clinical pharmacokinetics. (2002) [Pubmed]
  5. Angiotensin II directly induces muscle protein catabolism through the ubiquitin-proteasome proteolytic pathway and may play a role in cancer cachexia. Sanders, P.M., Russell, S.T., Tisdale, M.J. Br. J. Cancer (2005) [Pubmed]
  6. Inhibition of angiotensin-converting enzyme increases the nitric oxide levels in canine ischemic myocardium. Kitakaze, M., Node, K., Minamino, T., Asanuma, H., Ueda, Y., Kosaka, H., Kuzuya, T., Hori, M. J. Mol. Cell. Cardiol. (1998) [Pubmed]
  7. Clearance of imidapril, an Angiotensin-converting enzyme inhibitor, during hemodialysis in hypertensive renal failure patients: comparison with quinapril and enalapril. Tsuruoka, S., Kitoh, Y., Kawaguchi, A., Sugimoto, K., Hayasaka, T., Saito, T., Fujimura, A. Journal of clinical pharmacology (2007) [Pubmed]
  8. Single dose and steady state pharmacokinetics and pharmacodynamics of the ACE-inhibitor imidapril in hypertensive patients. Harder, S., Thürmann, P.A., Ungethüm, W. British journal of clinical pharmacology. (1998) [Pubmed]
  9. Pharmacokinetic and pharmacodynamic study of imidaprilat, an active metabolite of imidapril, a new angiotensin-converting enzyme inhibitor, in spontaneously hypertensive rats. Yamanaka, K., Takehara, N., Murata, K., Banno, K., Sato, T. Journal of pharmaceutical and biomedical analysis. (1997) [Pubmed]
  10. Role of kinin and renal ANG II blockade in acute effects of ACE inhibitors in low-renin hypertension. Naitoh, M., Suzuki, H., Arakawa, K., Matsumoto, A., Ichihara, A., Matsuda, H., Kubota, E., Murakami, M., Nakamoto, H., Saruta, T. Am. J. Physiol. (1997) [Pubmed]
  11. Different inhibition of enalaprilat and imidaprilat on bradykinin metabolizing enzymes. Sakamoto, K., Sugimoto, K., Fujimura, A. Life Sci. (2000) [Pubmed]
  12. Effect of .OH scavenging action by non-SH-containing angiotensin converting enzyme inhibitor imidaprilat using microdialysis. Obata, T., Yamanaka, Y. J. Physiol. Paris (1998) [Pubmed]
  13. Local renin-angiotensin system in sympathetic overactivity of spontaneously hypertensive rats. Nagase, M., Shimosawa, T., Ando, K., Fujita, T. Hypertens. Res. (1996) [Pubmed]
  14. Cellular mechanisms of cardioprotection afforded by inhibitors of angiotensin converting enzyme in ischemic hearts: role of bradykinin and nitric oxide. Kitakaze, M., Node, K., Takashima, S., Minamino, T., Kuzuya, T., Hori, M. Hypertens. Res. (2000) [Pubmed]
  15. Metabolic fate of the new angiotensin-converting enzyme inhibitor imidapril in animals. 7th communication: in vitro metabolism. Yamada, Y., Otsuka, M., Takaiti, O. Arzneimittel-Forschung. (1992) [Pubmed]
  16. Radioimmunoassay for imidapril, a new angiotensin-converting enzyme inhibitor, and imidaprilat, its active metabolite, in human plasma and urine. Yamanaka, K., Morikawa, S., Murata, K., Banno, K., Sato, T., Takai, T., Suzuki, T., Mizobe, M., Ito, M., Ishibashi, K. Journal of pharmaceutical and biomedical analysis. (1996) [Pubmed]
WikiGenes - Universities